Vigonvita Life Sciences (2630) Announces Proposal for H Share Full Circulation

Bulletin Express11-27

Vigonvita Life Sciences Co., Ltd. (Stock Code: 2630) announced that its board of directors has approved the implementation of H share full circulation. According to the announcement, 100,220,667 unlisted shares, representing approximately 59.7983% of the company’s total issued shares as of November 26, 2025, will be converted into H shares. The company plans to apply to the Hong Kong Stock Exchange for the listing of and permission to deal in these converted H shares.

No general meeting approval is required based on the company’s articles of association. The company has not yet submitted the application documents to the China Securities Regulatory Commission and will make further disclosures regarding the progress of the H share full circulation and subsequent listing procedures when appropriate. The relevant processes remain subject to necessary approvals from domestic and overseas regulatory authorities.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1168852122?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-27 16:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1168852122","market":"us","top_or_hot":-1,"title":"Vigonvita Life Sciences (2630) Announces Proposal for H Share Full Circulation","media":"Bulletin Express","content":"<p>Vigonvita Life Sciences Co., Ltd. (Stock Code: 2630) announced that its board of directors has approved the implementation of H share full circulation. According to the announcement, 100,220,667 unlisted shares, representing approximately 59.7983% of the company’s total issued shares as of November 26, 2025, will be converted into H shares. The company plans to apply to the Hong Kong Stock Exchange for the listing of and permission to deal in these converted H shares.</p>\n<p>No general meeting approval is required based on the company’s articles of association. The company has not yet submitted the application documents to the China Securities Regulatory Commission and will make further disclosures regarding the progress of the H share full circulation and subsequent listing procedures when appropriate. The relevant processes remain subject to necessary approvals from domestic and overseas regulatory authorities.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vigonvita Life Sciences (2630) Announces Proposal for H Share Full Circulation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVigonvita Life Sciences (2630) Announces Proposal for H Share Full Circulation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2025-11-27 16:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Vigonvita Life Sciences Co., Ltd. (Stock Code: 2630) announced that its board of directors has approved the implementation of H share full circulation. According to the announcement, 100,220,667 unlisted shares, representing approximately 59.7983% of the company’s total issued shares as of November 26, 2025, will be converted into H shares. The company plans to apply to the Hong Kong Stock Exchange for the listing of and permission to deal in these converted H shares.</p>\n<p>No general meeting approval is required based on the company’s articles of association. The company has not yet submitted the application documents to the China Securities Regulatory Commission and will make further disclosures regarding the progress of the H share full circulation and subsequent listing procedures when appropriate. The relevant processes remain subject to necessary approvals from domestic and overseas regulatory authorities.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02630","symbol_name":"旺山旺水-B","start_time":0,"source_url":"","article_id":"1168852122","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1168852122","pubTimestamp":1764232990,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Vigonvita Life Sciences Co., Ltd. (Stock Code: 2630) announced that its board of directors has approved the implementation of H share full circulation. According to the announcement, 100,220,667...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02630":"旺山旺水-B"},"translate_title":"Vigonvita Life Sciences(2630)公布H股全流通建议","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02630":1},"content_text":"Vigonvita Life Sciences Co., Ltd. (Stock Code: 2630) announced that its board of directors has approved the implementation of H share full circulation. According to the announcement, 100,220,667 unlisted shares, representing approximately 59.7983% of the company’s total issued shares as of November 26, 2025, will be converted into H shares. The company plans to apply to the Hong Kong Stock Exchange for the listing of and permission to deal in these converted H shares.\nNo general meeting approval is required based on the company’s articles of association. The company has not yet submitted the application documents to the China Securities Regulatory Commission and will make further disclosures regarding the progress of the H share full circulation and subsequent listing procedures when appropriate. The relevant processes remain subject to necessary approvals from domestic and overseas regulatory authorities.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"shareholding,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1168852122","isCrawlerRequest":true}